Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Revolutionizing Mental Health Treatment

Featured Submission, Featured Submission
1 Comment| August 16, 2021

{{labelSign}}  Favorites
{{errorMessage}}

(Click to play video.)

Click to enlarge
Cybin Inc. (NEO: CYBN, NYSE: CYBN, Forum) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and wellbeing.

The biotech company utilizes proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and potential treatment regimens for psychiatric disorders. Click the video above to learn more about Cybin's operations.

To find out more about the company, visit cybin.com.




FULL DISCLOSURE: Cybin Inc. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company